GlobeNewswire

Oxford Immunotec Announces New Initiative to Bring the Benefit of Modern Tuberculosis Testing to the Russian Federation

Del

OXFORD, United Kingdom and MARLBOROUGH, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced a new local production initiative to bring the benefits of the T-SPOT®.TB test to the Russian Federation.

Since the T-SPOT.TB test received approval in the Russian Federation in 2013, Oxford Immunotec has been working with a local distribution partner, PharmLine LLC (“PharmLine”) and has seen expanding uptake of the T-SPOT.TB test. In collaboration with PharmLine, Oxford Immunotec will now also be working with Generium Joint Stock Company (“Generium”), who will be manufacturing the T-SPOT.TB test locally at their factory in the Vladimir region of the Russian Federation. This is expected to reduce the cost of, and expand access to, the T-SPOT.TB test for patients in the Russian Federation. Additionally, Generium will be working with PharmLine on marketing and distribution of the T-SPOT.TB test, including applying for national TB control tenders.

The Russian Federation is among the 20 countries worldwide with the highest estimated numbers of incident TB cases, with a reported incidence rate of 60 cases per 100,000 population and a high rate of HIV/TB coinfection.1 The Russian Federation has the 3rd highest rate of multi-drug resistant TB in the world,2 which adds urgency to the need to reduce TB rates before drug resistance undermines the ability to successfully treat those diagnosed. With a strong commitment to new actions to end TB, the WHO and the Government of the Russian Federation convened the First WHO Global Ministerial Conference, Ending TB in the Sustainable Development Era: A Multisectoral Response, which was a fundamental milestone towards the United Nations General Assembly (UNGA) High-Level Meeting on TB in 2018. The development and implementation of more ambitious, fully-funded national TB policies and strategic plans is also one of many commitments included in the Moscow Declaration to End TB.3

The WHO and the UN have both recognized that a critical component in the fight to end TB is the rapid scaling up of access to and testing for TB infection in high-burden countries, particularly focusing on those most at risk of falling ill, such as children and those with HIV.4 They have also called on stakeholders to develop new models to increase access to the tools, such as interferon gamma release assays (IGRA) tests,5 which are now included in the WHO’s List of Essential In Vitro Diagnostics.6

“This new development allows Generium to bring into Russia a high-precision laboratory test for the diagnosis of tuberculosis infection, with the economic benefits of local production,” said Dmitriy Kudlay, CEO of Generium. “Together with PharmLine and Oxford Immunotec we are excited to expand the use of the T-SPOT.TB test in Russia in order to support the state’s aims in ending TB in the country.”  

“We are very pleased to enter into this exciting new approach with Generium, who as the skin test providers in Russia, have unparalleled reach and relationships within Russia and Kazakhstan,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. “We believe working with PharmLine and Generium expands the reach of the T-SPOT.TB test and we are proud to take another step forward in helping the clinical community in Russia in their fight against TB.” 

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company's T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

About Generium

Generium is the leading Russian biopharmaceutical company, focused on developing and commercializing diagnostic systems and pharmaceutical products for the treatment of orphan diseases, infection diseases, cancer, multiple sclerosis, myocardial infarction and strokes as well as tuberculosis diagnostic test - Diaskintest®. Generium consists of a high-end R&D center and a fully integrated manufacturing plant. Generium has more than 30 innovative products in the pipeline, including enzymes, monoclonal antibodies and ATMPs. Generium is headquartered in Moscow, Russia. Additional information can be found at www.generium.ru/en.

Diaskintest is a trademark of Generium Joint Stock Company.

About PharmLine

PharmLine was founded in 1993 and is a leading healthcare product distributor. PharmLine specializes in the marketing and sales of pharmaceuticals, diagnostic products and technologies for hospital and laboratory use in the Russian Federation and the Confederation of Independent States. PharmLine is located in Moscow, Russia.

Forward-Looking Statements

This release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this release are forward-looking statements. This includes statements about Oxford Immunotec's anticipated plans and objectives, future performance and revenues, financial condition, prospects for sales of its products, growth, strategies, expectations and objectives of management. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements contained in this release reflect Oxford Immunotec's current expectations and are subject to risks and uncertainties. Actual results may differ materially from those projected or implied by forward-looking statements. Other factors that could adversely affect Oxford Immunotec's business and prospects are described under the "Risk Factors" section in its filings with the Securities and Exchange Commission ("SEC"). Oxford Immunotec's SEC filings are available for free by visiting the investor section of its website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACTS:

Karen Koski
VP, Strategy & Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

Dmitriy Mamykin
The Head of International Department
Generium
Tel: +7 (495) 988-47-94 ext. 7073
bd@generium.ru

Vsevolod Letsko
PR Manager
Generium
Tel: +7 (495) 988-47-94 ext. 7020
pr@generium.ru

Mikhail Bokshtein
General Director
PharmLine LLC
m.bokshtein@pharmline.ru

____________________________________________

1 Global tuberculosis report 2018 (35). WHO; 2018
2 Global tuberculosis report 2018 (49). WHO; 2018
3 Moscow Declaration to End TB; First WHO Global Ministerial Conference on Ending TB in the Sustainable Development Era: A Multisectoral Response, November 2017. WHO and the Ministry of Health of the Russian Federation; 2017
4 Resolution adopted by the General Assembly on 10 October 2018: 73/3 Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis (5 – 6). United Nations General Assembly; 2018
5 Resolution adopted by the General Assembly on 10 October 2018: 73/3 Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis (10). United Nations General Assembly; 2018
6 World Health Organization Model List of Essential In Vitro Diagnostics – First Edition (2018). WHO; November 2018

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Next Green Wave Begins Cannabis Production18.4.2019 10:00:00 CESTPressemelding

NGW Authorized as Licensed Producer in Coalinga, California VANCOUVER, British Columbia, April 18, 2019 (GLOBE NEWSWIRE) -- Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) ("Next Green Wave", “NGW” or the "Company"), is excited to announce that it has obtained an Occupancy Permit for its first advanced indoor production facility from the City of Coalinga. The Company is now authorized as a licensed producer and is immediately advancing with its cannabis production by moving in over 10,000 plantlets to activate its growth cycle. Effective today, NGW will commence its cultivation program and receive its first plantlets to accommodate a perpetual harvest cycle comprised of approx. 50 yields per year. Each growth to point-of-sale cycle is expected to last four months. The building has been equipped with 14 climate-controlled flowering rooms which are expected to produce an average of 9,150 pounds of cannabis flower annually. The raw material and biomass grown from NGW’s facility wi

3Gtms Announces Strategic Investment by Sumeru Equity Partners17.4.2019 20:00:00 CESTPressemelding

Fastest growing Tier 1 TMS provider plans for accelerated growth and expansion SHELTON, Conn., April 17, 2019 (GLOBE NEWSWIRE) -- 3Gtms, Inc., a global provider of Tier 1 transportation management software solutions (TMS), announced that Sumeru Equity Partners (“SEP”)—a growth-focused technology investment firm—has made a strategic investment in the company to accelerate growth and product innovation. Terms were not disclosed. 3Gtms is the fastest growing Tier 1 TMS provider and has the highest customer satisfaction in the industry. The Company’s 3G-TM transportation management system is at the forefront of TMS innovation. The broad and deep multimodal TMS manages the full order-to-cash process in real time and within a single system for logistics service providers, shippers and brokers. Built on a reimagined architecture that delivers the power to self-configure, unique routing concepts and proprietary algorithms, 3G-TM is the only TMS in the world powerful enough to handle the most c

Mobile Network Operators Struggle to Prepare for 5G17.4.2019 16:00:00 CESTPressemelding

Infovista survey at MWC 2019 shows only 1 in 4 MNOs feel extremely prepared for 5G, lists top concerns and challenges ASHBURN, Va., April 17, 2019 (GLOBE NEWSWIRE) -- A new survey from Infovista, the leader in modern network performance, finds that only 25 percent of mobile network operators say they are extremely prepared for 5G, citing as their top concerns making sure their 5G network works correctly, the rollout stays within budgets, not being late to market and that the network meets subscriber needs. The survey also found that even fewer vendors who work with Mobile World Operators (MNOs) (just 1 in 6) feel MNOs are extremely prepared for 5G. Tweet This: Infovista Survey finds Mobile Operators Struggle to Prepare for #5G: https://www.infovista.com/blog/recent-survey-finds-mobile-network-operators-struggling-to-prepare-for-5g Infovista conducted the survey at MWC 2019 in Barcelona in February. The survey polled 145 attendees including MNOs, companies that work with MNOs and enterp

SNOMED International’s Global Patient Set: Navigating International Patient Care and Interoperability17.4.2019 15:00:00 CESTPressemelding

LONDON, April 17, 2019 (GLOBE NEWSWIRE) -- At SNOMED International’s April Business Meeting held in London last week, the organization announced to its Community of Practice the planned release of a Global Patient Set built from its globally recognized SNOMED CT clinical terminology standard. SNOMED International will release the Global Patient Set, or GPS, to support the cross border movement of information, and ultimately health system interoperability. Once released, the GPS, a controlled list of existing SNOMED CT unique concept identifiers, single descriptions and reference sets, will be available to all interested parties at no cost to users. The Chair of the organization’s General Assembly, Lies van Gennip, is delighted to share with health systems and industry what the Global Patient Set provides to Members and non-Members alike. “The Global Patient Set enables easier specification of EHR requirements, e.g. a patient summary, and results in improved interoperability. The Set wi

Radient Technologies Inc. Appoints Two New Members to its Board of Directors 17.4.2019 13:30:00 CESTPressemelding

EDMONTON, Alberta, April 17, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce that it has appointed Ms. Jocelyne F. Lafrenière and Mr. Yves Gougoux to its Board of Directors, effective upon approval by Health Canada. “We are delighted to be bringing these two very accomplished individuals onto our Board of Directors, and expanding our Board in the process”, commented Frank Ferlaino, Chairman of Radient’s Board of Directors. “As Radient continues to grow its operations globally by entering into new geographical markets and increasing its market presence in highly competitive industries, the expertise and knowledge that both Ms. Lafrenière and Mr. Gougoux bring to the Company will be invaluable. We look forward to welcoming them to our team.” Ms. Jocelyne F. Lafreni è re, CPA, CA, CICA, CPSC , Adm.A : Ms. Lafrenière is the President & Chief Executive Officer of JFL International Inc., a management cons

Bona Releases 2018 Sustainability Report17.4.2019 12:18:00 CESTPressemelding

Report Highlights Company Benchmarks for Betterment of Global Sustainability Initiatives Malmo, Sweden, April 17, 2019 (GLOBE NEWSWIRE) -- Today, Bona, the global leader in hardwood floor care and maintenance since 1919, released its 2018 sustainability report. An industry pioneer in creating products and processes for the betterment of worldwide sustainability, the report highlights benchmarks and achievements in Bona’s journey for a more sustainable future. “Acting sustainably and taking responsibility for our climate footprint has never been a more important for Bona and the broader business community,” said Kerstin Lindell, CEO of Bona. “The 2018 sustainability report is an important milestone for Bona showcasing our commitment to innovation and sustainability for this past year and for years to come.” Since the company’s inception in 1919, sustainability has been central to the business. From the launch of the first-ever waterborne hardwood floor finish in 1979 to its years of enc